Ads
related to: multiple myeloma- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Contact a Representative
For Questions and Information
About This Treatment
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Primary and Subgroup Data
Search results
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Morningstar· 6 days agoKite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple ...
Cancer death rates are dropping, but not for everyone
Scripps News via AOL· 2 hours agoUnfortunately, a number of health disparities remain, such as: Black men are twice as likely to die...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 12 minutes agoEHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress PR Newswire SUZHOU, China and ROCKVILLE, Md., May 15, 2024 SUZHOU, China and ROCKVILLE
Purses' auction to support cancer patients, caregivers
WISH-TV Indianapolis· 59 minutes agoA group is using purses and philanthropy together for a good cause. Purses with Purpose aims to...
Kite and Arcellx prepare to launch Phase III multiple myeloma trial
Clinical Trials Arena via Yahoo Finance· 6 days agoKite, a Gilead Company, and Arcellx have announced plans to commence a Phase III clinical trial of...
Kowalewski: Honoring my mom’s dying request: ‘Tell my story’
Standard-Examiner· 19 hours agoSix months before my mom died, she began writing memories in a spiral-bound notebook. Once multiple ...
Earnings call: Legend Biotech reports robust growth with CARVYKTI By Investing.com
Investing.com· 2 days agoLegend Biotech (NASDAQ: LEGN) has announced significant growth in its first-quarter financial...
Kite and Arcellx to start Phase 3 trial for myeloma therapy By Investing.com
Investing.com· 6 days ago(NASDAQ: ACLX) have announced their upcoming Phase 3 clinical trial for anitocabtagene autoleucel...
Arcellx shares target raised by Stifel on study design By Investing.com
Investing.com· 15 hours agoThe adjustment follows the company's announcement regarding the design of a phase 3 study for...
Dangers firefighters face include higher cancer risks
United Press International via Yahoo News· 5 days agoFor 14 years, David Perez fought fires in South Florida, thinking he was in peak physical shape....
